CGP7040

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412731

CAS#: 122188-44-7

Description: CGP7040 is a rifamycin analogue, is a protein 50S ribosomal subunit inhibitor that was being developed by Novartis.

Chemical Structure

img
CGP7040
CAS# 122188-44-7
Instruction

Theoretical Analysis

MedKoo Cat#: 412731
Name: CGP7040
CAS#: 122188-44-7
Chemical Formula: C51H67N3O12
Exact Mass: 913.47
Molecular Weight: 914.110
Elemental Analysis: C, 67.01; H, 7.39; N, 4.60; O, 21.00

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CGP7040; CGP 7040; CGP-7040;

IUPAC/Chemical Name: 3-(2,4,6-Trimethylbenzylpiperazinyl)rifamycin SV

InChi Key: ILHGDLYAJLWSGO-YAAICTFBSA-N

InChi Code: InChI=1S/C51H67N3O12/c1-25-22-28(4)35(29(5)23-25)24-53-17-19-54(20-18-53)41-40-45(59)38-37(46(41)60)39-48(33(9)44(38)58)66-51(11,49(39)61)64-21-16-36(63-12)30(6)47(65-34(10)55)32(8)43(57)31(7)42(56)26(2)14-13-15-27(3)50(62)52-40/h13-16,21-23,26,30-32,36,42-43,47,56-60H,17-20,24H2,1-12H3,(H,52,62)/b14-13+,21-16+,27-15-/t26-,30+,31+,32-,36-,42-,43-,47+,51-/m0/s1

SMILES Code: CO[C@H]1/C=C/O[C@@]2(C)OC3=C(C(O)=C(C(O)=C(C(N4CCN(CC5=C(C)C=C(C)C=C5C)CC4)=C6O)NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H](OC(C)=O)[C@@H]1C)=O)C6=C3C2=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 914.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle. 1987 Sep;68(3):177-82. doi: 10.1016/0041-3879(87)90053-5. PMID: 2834842.

2: Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 1990 Mar;141(3):626-30. doi: 10.1164/ajrccm/141.3.626. PMID: 2155555.

3: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Japanese. PMID: 9883617.

4: Amitani R, Kuze F. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Kekkaku. 1994 Nov;69(11):711-7. Japanese. PMID: 7837725.

5: Klemens SP, Cynamon MH. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother. 1991 Oct;35(10):2026-30. doi: 10.1128/aac.35.10.2026. PMID: 1662021; PMCID: PMC245319.

6: Dickinson JM, Mitchison DA. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183-93. doi: 10.1016/0041-3879(87)90054-7. PMID: 2834843.

7: Pedroso de Lima MC, Chiche BH, Debs RJ, Düzgüneş N. Interaction of antimycobacterial and anti-pneumocystis drugs with phospholipid membranes. Chem Phys Lipids. 1990 Mar;53(4):361-71. doi: 10.1016/0009-3084(90)90034-o. PMID: 2160335.